Literature DB >> 22197772

Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.

Waseem Kaialy1, Martyn Ticehurst, Ali Nokhodchi.   

Abstract

The purpose of this study was to evaluate the relationships between physicochemical properties and aerosolisation performance of different grades of lactose. In order to get a wide range of physicochemical properties, various grades of lactose namely Flowlac 100 (FLO), Lactopress anhydrous 250 (LAC), Cellactose 80 (CEL), Tablettose 80 (TAB), and Granulac 200 (GRA) were used. The different lactose grades were carefully sieved to separate 63-90 μm particle size fractions and then characterised in terms of size, shape, density, flowability, and solid state. Formulations were prepared by blending each lactose with salbutamol sulphate (SS) at ratio of 67.5:1 (w/w), and then evaluated in terms of SS content uniformity, lactose-SS adhesion properties, and in vitro aerosolisation performance delivered from the Aerolizer. Sieved lactose grades showed similar particle size distributions (PSDs) and good flow properties but different particle shape, particle surface texture, and particle solid state. Content uniformity assessments indicated that lactose particles with rougher surface produced improved SS homogeneity within DPI formulation powders. Lactose-SS adhesion assessments indicated that lactose particles with more elongated shape and the rougher surface showed smaller adhesion force between lactose and salbutamol sulphate. Lactose powders with higher bulk density and higher tap density produced smaller emission (EM) and higher drug loss (DL) of SS. In vitro aerosolisation for various lactose grades followed the following rank order in terms of deposition performance: GRA>TAB>LAC ≈ CEL>FLO. Linear relationships were established showing that in order to maximize SS delivery to lower airway regions, lactose particles with more elongated shape, more irregular shape, and rougher surface are preferred. Therefore, considerable improvement in DPI performance can be achieved by careful selection of grade of lactose included within DPI formulations.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197772     DOI: 10.1016/j.ijpharm.2011.12.018

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.

Authors:  Waseem Kaialy; Hassan Larhrib; Gary P Martin; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

2.  Chitosan-based binary dry powder inhaler carrier with nanometer roughness for improving in vitro and in vivo aerosolization performance.

Authors:  Ying Huang; Zhengwei Huang; Xuejuan Zhang; Ziyu Zhao; Xuan Zhang; Kexin Wang; Cheng Ma; Chune Zhu; Xin Pan; Chuanbin Wu
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler.

Authors:  Waseem Kaialy; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-10-16       Impact factor: 4.200

4.  Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres.

Authors:  Waseem Kaialy; Tariq Hussain; Amjad Alhalaweh; Ali Nokhodchi
Journal:  Pharm Res       Date:  2013-08-06       Impact factor: 4.200

5.  Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations.

Authors:  Adam Pacławski; Jakub Szlęk; Raymond Lau; Renata Jachowicz; Aleksander Mendyk
Journal:  Int J Nanomedicine       Date:  2015-01-21

Review 6.  Influence of physical properties of carrier on the performance of dry powder inhalers.

Authors:  Tingting Peng; Shiqi Lin; Boyi Niu; Xinyi Wang; Ying Huang; Xuejuan Zhang; Ge Li; Xin Pan; Chuanbin Wu
Journal:  Acta Pharm Sin B       Date:  2016-05-04       Impact factor: 11.413

7.  Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations.

Authors:  Carlos Molina; Waseem Kaialy; Qiao Chen; Daniel Commandeur; Ali Nokhodchi
Journal:  Drug Deliv Transl Res       Date:  2018-12       Impact factor: 4.617

8.  Design and Characterization of Atorvastatin Dry Powder Formulation as a potential Lung Cancer Treatment.

Authors:  Alaa S Tulbah; Amr Gamal
Journal:  Saudi Pharm J       Date:  2021-11-11       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.